Highlights: * There have now been 137 patients implanted in 19 centres worldwide, with over 65 years cumulative patient experience to date, with longest ongoing patient >1020 days * Strong revenue growth in all markets - $4.9 million (FY2006 - $1.1 million) * Key regulatory approvals gained in US, Europe and Australia * Cash use $30.8 million in line with expectations * Cash reserves of $48.6 million as at June 2007 * Growing body of clinical evidence driving LVAD market growth * Poised for significant revenue growth in FY2008.
